Pierre-Luc Boudreault

Prix et distinctions

• (2008) FQRNT Postdoctoral Research Scholarship. Fonds de recherche du Québec Nature et technologies.
• (2005) NSERC - Canada Graduate Scholarships-Doctoral program. Natural Sciences and Engineering Research Council of Canada.
• (2002) FQRNT - Master's (B1X) Research Scholarships. Fonds de recherche du Québec Nature et technologies.

Financement

• Subvention. Exploiter le potentiel du récepteur ACKR3: Une alternative audacieuse pour un traitement sécuritaire de la douleur sans dépendance aux opioïdes. Fonds de Recherche du Québec – Nature et Technologies (Montreal, Canada). 100 000 $. (2025-2026).
  Numéro de subvention : 374464. Voir plus
• Subvention. Validation des approches d'intelligence artificielle et d'apprentissage machine pour la conception, l'optimisation et la synthèse d'outils moléculaires visant à étudier et comprendre le rôle des protéases transmembranaires à sérine de type 2. Fonds de Recherche du Québec – Nature et Technologies (Montreal, Canada). 90 000 $. (2024-2027).
  Numéro de subvention : 362706. Voir plus
• Subvention. Targeting Apelin Signaling for the Treatment of Muscular Dystrophy. Canadian Institutes of Health Research (Ottawa, Canada). 841 500 $. (2024-2029).
  Numéro de subvention : 202309PJT. Voir plus
• Subvention. Mimicking the secondary structures of proteins and peptides to modulate Protein-Protein Interactions. Natural Sciences and Engineering Research Council (Ottawa, Canada). 25 000 $. (2023-2024).
  Numéro de subvention : RGPIN-2022-04028. Voir plus
• Subvention. ATP Synthase as an emerging target for the pre-clinical development of broad-spectrum antibacterial agents against drug-resistant bacterial infections. Canadian Institutes of Health Research (Ottawa, Canada). 100 000 $. (2023-2024).
  Numéro de subvention : 202209ARB. Voir plus
• Subvention. Pre-clinical development of broad-spectrum antiviral strategies against human respiratory viruses of pandemic concern. Canadian Institutes of Health Research (Ottawa, Canada). 945 541 $. (2022-2026).
  Numéro de subvention : 202203PJT. Voir plus
• Subvention. Mimicking the secondary structures of proteins and peptides to modulate Protein-Protein Interactions. Natural Sciences and Engineering Research Council (Ottawa, Canada). 12 500 $. (2022-2023).
  Numéro de subvention : DGECR-2022-00010. Voir plus
• Subvention. Increasing the capacity and quality of chemical libraries. MEI - Médicament Québec (Québec, Canada). 369 443 $. (2022-2024).
• Subvention. Optimization of a Brain-Penetrant NTS2 Non-Opioid Analgesic Lead. Ministère de l'Économie, de la Science et de l'Innovation - Québec (QC, Canada). 625 000 $. (2022-2024).
• Subvention. Antibioswitch : a new class of antibiotics for treating Staphylococcus aureus infections in humans. IPS Innovation (Sherbrooke, Canada). 30 000 $. (2022-2024).
• Subvention. Journey to the Center of the Cell: Reprogramming intracellular transport to the nucleus enhances HER2+ tumor killing for trastuzumab conjugated to payloads active in the nucleus. Canadian Institutes of Health Research (Ottawa, Canada). 589 400 $. (2021-2026).
  Numéro de subvention : 202104PJT. Voir plus
• Subvention. Start-up Grant. FMSS and CRCHUS (Sherbrooke, Canada). 40 000 $. (2021-2023).
• Subvention. Acuité-Qc Consortium: predicting and visualizing drug action. Québec Consortium for Drug Discovery (Montreal, Canada). 26 398 352 $. (2021-2024).
• Subvention. Use of the peptide transporter Angiopep-2 for the passage of non-permeable radiotracers across the blood-brain barrier. Axe Imagerie Médicale du CRCHUS, Centre Imagerie Médicale Sherbrooke (Sherbrooke, Canada). 15 000 $. (2021-2022).
• Subvention. Reprogramming intracellular transport to the nucleus enhances HER2+ tumor killing for trastuzumab conjugated to payloads active in the nucleus. Canadian Institutes of Health Research (ON, Canada). 581 400 $. (2021-2026).
• Subvention. Development of a new class of antibiotics specific for Staphylococcus and bovine mastitis. Regroupement FRQNT pour un lait de qualité optimale Op+Lait (Québec, Canada). 22 500 $. (2021-2022).
• Contrat. Synthesis of macrocycles - proprietary molecules. Bayer AG (Wuppertal, Allemagne). 1 300 000 $. (2021-2026).
• Subvention. Targeting TMPRSS6 to treat hepcidin-deficiency disorders. Canadian Institutes of Health Research (ON, Canada). 960 075 $. (2021-2025).
• Subvention. The Apelin receptor as target for heart failure. Canadian Institutes of Health Research (ON, Canada). 665 000 $. (2021-2022).
• Subvention. Structure-function and dynamics of the apelin receptor, a promising target for cardiovascular diseases. Fonds de Recherche du Québec - Santé (QC, Canada). 381 000 $. (2021-2023).
• Subvention. Cell-based plasmonic biosensor for the quantification of SARS-CoV-2 incorporation in live cells. IPS-Innovation fund (Sherbrooke, Canada). 40 000 $. (2021-2023).
• Subvention. Exploiting ELABELA and analogs to protect from septic shock. Canadian Institutes of Health Research (ON, Canada). 318 431 $. (2021-2023).
• Subvention. Role, regulation, and functions of the delta opioid receptor in the treatment of pain. Canadian Institutes of Health Research (ON, Canada). 967 725 $. (2021-2023).
• Subvention. Preventing SARS-CoV-2 infection by targeting human type II transmembrane serine protease activity. Canadian Institutes of Health Research (ON, Canada). 856 000 $. (2021-2022).
• Subvention. Targeting Endogenous Repair: A Novel Mutation Independent Pharmacological Approach for the Treatment of Muscular Dystrophy. Stem Cell Network (ON, Canada). 62 233 $. (2021-2022).
• Subvention. Functional and structural understanding of angiotensin II type 1 receptor biased signaling. Canadian Institutes of Health Research (Ottawa, Canada). 1 189 576 $. (2020-2025).
  Numéro de subvention : 202003PJT. Voir plus
• Subvention. Functional and structural understanding of angiotensin II type 1 receptor biased signaling. Canadian Institutes of Health Research (ON, Canada). 1 189 576 $. (2020-2025).
  Numéro de subvention : PJT-173504.
• Subvention. Bacterial ATP synthase inhibitors – A novel approach toward antibiotics targeting difficultto- treat Gram-positive and Gram-negative bacterial infections. Amorchem Therapeutics and CQDM (Montreal, Canada). 1 459 041 $. (2020-2021).
• Contrat. Generation of spatial epitopes for membrane targets (GPCR). Immune Biosolutions (Sherbrooke, Canada). 30 690 $. (2020-2022).
• Subvention. New antibiotic combination for MRSA and Pseudomonas aeruginosa in cystic fibrosis. Cystic Fibrosis Canada (ON, Canada). 300 000 $. (2018-2021).
• Subvention. Synthèse de peptides procytolitiques modifiés spécifiques aux cellules cancéreuses de la prostate. Natural Sciences and Engineering Research Council (Ottawa, Canada). 21 000 $. (2005-2006).
  Numéro de subvention : grant.2905108. Voir plus

Publications

Articles

• Loubane, G., Robert, G., Firdaus, S.B., Robidas, R., Comeau, C., Boudreault, P.-L., Komba, J.E., Gagnon, H., Wagner, J.R., Naylor, S., Klarskov, K. (2026). Structural characterization of a L-dehydroascorbic acid–L-homocysteine thiolactone reaction product: Intracellular formation in neuronal cells. Biochimica Et Biophysica Acta General Subjects. DOI
• Gitlin-Domagalska, A., Hassanzadeh, M., Helbik-Maciejewska, A., Lepage, M., Joushomme, A., Désilets, A., Dębowski, D., Boudreault, P.-L., Leduc, R., Rolka, K. (2026). Structural insights into frog skin-derived cyclic peptides as selective matriptase inhibitors. European Journal of Medicinal Chemistry. DOI
• Walid Guerrab, Matthieu Lepage, Antoine Désilets, Alexandre Joushomme, Michael Desgagné, Ulrike Froehlich, Richard Leduc, Pierre-Luc Boudreault. (2025). Structure-Guided Optimization of Selective Covalent Reversible Peptidomimetic Inhibitors Targeting TMPRSS6. Journal of Medicinal Chemistry. DOI
• Andréanne Laniel, Brian Holleran, Émy Labonté, Sarah-Janne Grondin, Pierre-Luc Boudreault, Christine Lavoie. (2025). Class A and B GPCRs trigger rapid Gαs translocation to late and slow recycling endosomes. Communications Biology. DOI
• Yuguo Liu, Svenja C. Schüler, Simon Dumontier, Frederic Balg, Sonia Bedard, Thibaut Desgeorges, Jerome N. Feige, Pierre-Luc Boudreault, C. Florian Bentzinger. (2025). TGFβ-Smad3 signaling restores cell-autonomous Srsf1-mediated splicing of fibronectin in aged skeletal muscle stem cells. Nature Communications. DOI
• Evelyne Lacasse, Renaud Binette, Héloïse Guibout, Riu Liu, Yun-Ming Lin, Manuka Ghosh, Pierre-Luc Boudreault, Marvin J. Miller, François Malouin. (2025). Unraveling the mechanisms behind the enhanced efficacy of β-lactam-based sideromycins. Communications Biology. DOI
• Juan Antonio Contreras Vite, Alexandria Tiffinger, Léa Théroux, Nathalie Morin, Mannix Auger-Messier, Pierre-Luc Boudreault, Philippe Sarret, Olivier Lesur, Robert Dumaine. (2025). A Metabolically Stable Apelin-13 Analog Acting as a Potent ITo Potassium Current Blocker with Potential Benefits for Brugada Syndrome. International Journal of Molecular Sciences. DOI
• Brouillette, R.L., Mona, C.E., Desgagné, M., Hassanzedeh, M., Breault, É., Lussier, F., Belleville, K., Longpré, J.-M., Grandbois, M., Boudreault, P.-L., Besserer-Offroy, É., Sarret, P. (2025). A lipidated peptide derived from the C-terminal tail of the vasopressin 2 receptor shows promise as a new β-arrestin inhibitor. Pharmacological Research. DOI
• Gruber, C.W., Beets, I., Boudreault, P.-L., Bolzani, V.D.S., Carlsson, J., Fernandes, P.A., Freissmuth, M., Gilles, N., Göransson, U., Hauser, A.S., Heinis, C., Kool, J., Lubell, W.D., Modica, M.V., Selent, J., Tytgat, J., Undheim, E.A.B., Chaigneau, M., Iturrioz, X., ... Shukla, A. (2025). Biodiversity2Drugs—Renaissance of exploring nature-derived peptides for GPCR ligand discovery. British Journal of Pharmacology. DOI
• Shauna Barreto, Renaud Binette, Alexandre Murza, Jean Legault, André Pichette, Pierre-Luc Boudreault, Samuel Couve-Bonnaire, Thomas Castanheiro. (2025). Cu-catalyzed photoredox chlorotrifluoromethylation of polysubstituted alkenes and pharmacological evaluation. Organic & Biomolecular Chemistry. DOI
• Joushomme, A., Désilets, A., Champagne, W., Hassanzadeh, M., Lemieux, G., Gravel-Trudeau, A., Lepage, M., Lafrenière, S., Froehlich, U., List, K., Boudreault, P.-L., Leduc, R. (2025). Development of ketobenzothiazole-based peptidomimetic TMPRSS13 inhibitors with low nanomolar potency. Journal of Enzyme Inhibition and Medicinal Chemistry. DOI
• Nguyen, D.T., Desgagné, M., Laniel, A., Lavoie, C., Boudreault, P.-L. (2025). Diversity-oriented synthesis of second generation guanidinium-rich transporters toward cell-selective penetration. Bioorganic Chemistry. DOI
• Lemieux, G., Pérez-Vargas, J., Désilets, A., Hassanzadeh, M., Thompson, C.A.H., Gravel-Trudeau, A., Joushomme, A., Ennis, S., Villanueva, I., Marouseau, E., Fraser, B.J., Champagne, W., Lepage, M., Niikura, M., Arrowsmith, C.H., Jean, F., Leduc, R., Boudreault, P.-L. (2025). From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants. Journal of Medicinal Chemistry. DOI
• Ferková, S., Lepage, M., Désilets, A., Assouvie, K., Lemieux, G., Brochu, I., Froehlich, U., Gravel-Trudeau, A., Vastra, J., Jean, F., Sarret, P., Leduc, R., Boudreault, P.-L. (2025). Optimizing the pharmacokinetics and selectivity of TMPRSS2 inhibitors. European Journal of Medicinal Chemistry. DOI
• (2025). Revolutionizing Peptide Discovery: AI-Driven Drug Design Paving the Way for the Future of Cell & Gene Therapy. MOLECULAR THERAPY.
• Fraser, B.J., Wilson, R.P., Ferková, S., Ilyassov, O., Lac, J., Dong, A., Li, Y.-Y., Seitova, A., Li, Y., Hejazi, Z., Kenney, T.M.G., Penn, L.Z., Edwards, A., Leduc, R., Boudreault, P.-L., Morin, G.B., Bénard, F., Arrowsmith, C.H. (2025). Structural basis of TMPRSS11D specificity and autocleavage activation. Nature Communications. DOI
• Lanoie, A., Ferková, S., Caron-Duval, É., Dallagnol, J.C.C., Diarra, S., Murza, A., Tremblay, A., Théroux, L., Breault, É., Ranjbaran, A., Landry, L., Côté, J., Longpré, J.-M., Boudreault, P.-L., Chatenet, D., Sarret, P. (2025). Structure-activity relationships of contulakin-G: Design, synthesis, and characterization of Thr10 analogs for pain modulation. Biomedicine and Pharmacotherapy. DOI
• Michael Desgagné, Magali Chartier, Camille Lagard, Sára Ferková, Mathieu Choquette, Jean‐Michel Longpré, Jérôme Côté, Pierre‐Luc Boudreault, Philippe Sarret. (2024). Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics. Angewandte Chemie. DOI
• Michael Desgagné, Magali Chartier, Camille Lagard, Sára Ferková, Mathieu Choquette, Jean‐Michel Longpré, Jérôme Côté, Pierre‐Luc Boudreault, Philippe Sarret. (2024). Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics. Angewandte Chemie International Edition. DOI
• (2024). A series of novel, selective matriptase inhibitors. JOURNAL OF PEPTIDE SCIENCE.
• Moal, E.L., Liu, Y., Collerette-Tremblay, J., Dumontier, S., Fabre, P., Molina, T., Dort, J., Orfi, Z., Denault, N., Boutin, J., Michaud, J., Giguère, H., Desroches, A., Trân, K., Ellezam, B., Vézina, F., Bedard, S., Raynaud, C., Balg, F., ... Bentzinger, C.F. (2024). Apelin stimulation of the vascular skeletal muscle stem cell niche enhances endogenous repair in dystrophic mice. Science Translational Medicine. DOI
• Ferková, S., Froehlich, U., Nepveu-Traversy, M.-É., Murza, A., Azad, T., Grandbois, M., Sarret, P., Lavigne, P., Boudreault, P.-L. (2024). Comparative Analysis of Cyclization Techniques in Stapled Peptides: Structural Insights into Protein–Protein Interactions in a SARS-CoV-2 Spike RBD/hACE2 Model System. International Journal of Molecular Sciences. DOI
• (2024). Functional and structural understanding of the angiotensin II receptor type 1 (AT1R) biased signaling. JOURNAL OF PEPTIDE SCIENCE.
• (2024). Harnessing GPCRs biased signaling: novel macrocyclic analogs for enhanced cardiovascular treatment with reduced side effects. JOURNAL OF PEPTIDE SCIENCE.
• Ly, H.M., Desgagné, M., Nguyen, D.T., Comeau, C., Froehlich, U., Marsault, E., Boudreault, P.-L. (2024). Insights on Structure-Passive Permeability Relationship in Pyrrole and Furan-Containing Macrocycles. Journal of Medicinal Chemistry. DOI
• Langlois, J.-P., Larose, A., Brouillette, E., Delbrouck, J.A., Boudreault, P.-L., Malouin, F. (2024). Mode of Antibacterial Action of Tomatidine C3-Diastereoisomers. Molecules. DOI
• (2024). Molecular dynamics insights into AT1 receptor variants: towards the design of potent biased agonists. JOURNAL OF PEPTIDE SCIENCE.
• Pérez-Vargas, J., Lemieux, G., Thompson, C.A.H., Désilets, A., Ennis, S., Gao, G., Gordon, D.G., Schulz, A.L., Niikura, M., Nabi, I.R., Krajden, M., Boudreault, P.-L., Leduc, R., Jean, F. (2024). Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals. Antiviral Research. DOI
• Colombo, É., Désilets, A., Hassanzadeh, M., Lemieux, G., Marois, I., Cliche, D., Delbrouck, J.A., Murza, A., Jean, F., Marsault, E., Richter, M.V., Leduc, R., Boudreault, P.-L. (2024). Optimization of Ketobenzothiazole-Based Type II Transmembrane Serine Protease Inhibitors to Block H1N1 Influenza Virus Replication. Chemmedchem. DOI
• (2024). Optimization of a promising inhibitor of TMPRSS2 as a an early treatment option againts COVID-. JOURNAL OF PEPTIDE SCIENCE.
• Desgagné, M., Désilets, A., Ferková, S., Lepage, M., Perreault, O., Joushomme, A., Lemieux, G., Guerrab, W., Froehlich, U., Comeau, C., Sarret, P., Leduc, R., Boudreault, P.-L. (2024). Rational In Silico Design of Selective TMPRSS6 Peptidomimetic Inhibitors via Exploitation of the S2 Subpocket. Journal of Medicinal Chemistry. DOI
• Shkreta, L., Toutant, J., Delannoy, A., Durantel, D., Salvetti, A., Ehresmann, S., Sauvageau, M., Delbrouck, J.A., Gravel-Trudeau, A., Comeau, C., Huard, C., Coulombe-Huntington, J., Tyers, M., Grierson, D., Boudreault, P.-L., Chabot, B. (2024). The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response. Oncotarget. DOI
• Pérez-Vargas, J., Worrall, L.J., Olmstead, A.D., Ton, A.-T., Lee, J., Villanueva, I., Thompson, C.A.H., Dudek, S., Ennis, S., Smith, J.R., Shapira, T., De Guzman, J., Gang, S., Ban, F., Vuckovic, M., Bielecki, M., Kovacic, S., Kenward, C., Hong, C.Y., ... Jean, F. (2023). A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants. Emerging Microbes and Infections. DOI
• Robillard, S., Trân, K., Lachance, M.-S., Brazeau, T., Boisvert, E., Lizotte, F., Auger-Messier, M., Boudreault, P.-L., Marsault, É., Geraldes, P. (2023). Apelin prevents diabetes-induced poor collateral vessel formation and blood flow reperfusion in ischemic limb. Frontiers in Cardiovascular Medicine. DOI
• L'Exact, M., Comeau, C., Bourhis, A., Boisvert, O., Fröhlich, U., Létourneau, D., Marsault, É., Lavigne, P., Grandbois, M., Boudreault, P.-L. (2023). Beyond Rule-of-five: Permeability Assessment of Semipeptidic Macrocycles. Biochimica Et Biophysica Acta Biomembranes. DOI
• Laniel, A., Marouseau, E., Nguyen, D.T., Froehlich, U., McCartney, C., Boudreault, P.-L., Lavoie, C. (2023). Characterization of PGua4, a Guanidinium-Rich Peptoid that Delivers IgGs to the Cytosol via Macropinocytosis. Molecular Pharmaceutics. DOI
• Loubane, G., Robert, G., Firdaus, S.B., Venne, P., Comeau, C., Boudreault, P.-L., Komba, J.E., Wagner, J.R., Naylor, S., Klarskov, K. (2023). Conundrum of dehydroascorbic acid and homocysteine thiolactone reaction products: Structural characterization and effect on peptide and protein N-homocysteinylation. Free Radical Biology and Medicine. DOI
• Perez-Vargas, J., Shapira, T., Olmstead, A.D., Villanueva, I., Thompson, C.A.H., Ennis, S., Gao, G., De Guzman, J., Williams, D.E., Wang, M., Chin, A., Bautista-Sanchez, D., Agafitei, O., Levett, P., Xie, X., Nuzzo, G., Freire, V.F., Quintana-Bulla, J.I., Bernardi, D.I., ... Jean, F. (2023). Corrigendum to “Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics” “Antiviral Research 209 (2023)/105484” (Antiviral Research (2023) 209, (S0166354222002534), (10.1016/j.antiviral.2022.105484)). Antiviral Research. DOI
• Pérez-Vargas, J., Shapira, T., Olmstead, A.D., Villanueva, I., Thompson, C.A.H., Ennis, S., Gao, G., De Guzman, J., Williams, D.E., Wang, M., Chin, A., Bautista-Sánchez, D., Agafitei, O., Levett, P., Xie, X., Nuzzo, G., Freire, V.F., Quintana-Bulla, J.I., Bernardi, D.I., ... Jean, F. (2023). Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics. Antiviral Research. DOI
• (2023). Encapsulated-Type Iridium(III) Phosphorescent Emitters with a Hexadentate Ligand of Three Different Bidentate Units. ORGANOMETALLICS. DOI
• Delbrouck, J.A., Murza, A., Diachenko, I., Ben Jamaa, A., Devi, R., Larose, A., Chamberland, S., Malouin, F., Boudreault, P.-L. (2023). From garden to lab: C-3 chemical modifications of tomatidine unveil broad-spectrum ATP synthase inhibitors to combat bacterial resistance. European Journal of Medicinal Chemistry. DOI
• Millette, G., Lacasse, E., Binette, R., Belley, V., Chaumont, L.-P., Ster, C., Beaudry, F., Boyapelly, K., Boudreault, P.-L., Malouin, F. (2023). Rationally Designed Pyrimidine Compounds: Promising Novel Antibiotics for the Treatment of Staphylococcus aureus-Associated Bovine Mastitis. Antibiotics. DOI
• Théroux, L., Van Den Hauwe, R., Trân, K., Fournier, J., Desgagné, M., Meneboo, N., Lavallée, A., Fröhlich, U., Côté, J., Hollanders, C., Longpré, J.-M., Murza, A., Marsault, E., Sarret, P., Boudreault, P.-L., Ballet, S. (2023). Signaling Modulation via Minimal C-Terminal Modifications of Apelin-13. ACS Pharmacology and Translational Science. DOI
• Delbrouck, J.A., Desgagné, M., Comeau, C., Bouarab, K., Malouin, F., Boudreault, P.-L. (2023). The Therapeutic Value of Solanum Steroidal (Glyco)Alkaloids: A 10-Year Comprehensive Review. Molecules. DOI
• Shapira, T., Monreal, I.A., Dion, S.P., Buchholz, D.W., Imbiakha, B., Olmstead, A.D., Jager, M., Désilets, A., Gao, G., Martins, M., Vandal, T., Thompson, C.A.H., Chin, A., Rees, W.D., Steiner, T., Nabi, I.R., Marsault, E., Sahler, J., Diel, D.G., ... Jean, F. (2022). A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature. DOI
• Binette, R., Desgagné, M., Theaud, C., Boudreault, P.-L. (2022). Efficient Fmoc-Protected Amino Ester Hydrolysis Using Green Calcium(II) Iodide as a Protective Agent. Molecules. DOI
• (2022). Size-Reduced Macrocyclic Analogues of [Pyr<SUP>1</SUP>]-apelin-13 Showing Negative Gα₁₂ Bias Still Produce Prolonged Cardiac Effects. JOURNAL OF MEDICINAL CHEMISTRY. DOI
• Chad Normandin, Pierre-Luc Boudreault. (2021). Concise Large-Scale Synthesis of Tomatidine, A Potent Antibiotic Natural Product. Molecules. DOI
• (2021). Macrocycles as Inhibitors of Protein-Protein Interactions. INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS.
• (2021). Modulation of the Passive Permeability of Semipeptidic Macrocycles: N- and C-Methylations Fine-Tune Conformation and Properties. JOURNAL OF MEDICINAL CHEMISTRY. DOI
• (2021). Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog. BIOMEDICINE & PHARMACOTHERAPY. DOI
• (2020). Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract - A review of patent literature. EXPERT OPINION ON THERAPEUTIC PATENTS. DOI
• (2020). Structure-Permeability Relationship of Semipeptidic Macrocycles-Understanding and Optimizing Passive Permeability and Efflux Ratio. JOURNAL OF MEDICINAL CHEMISTRY. DOI
• (2019). Discovery and Development of TMPRSS6 Inhibitors Modulating Hepcidin Levels in Human Hepatocytes. CELL CHEMICAL BIOLOGY. DOI
• (2019). Suzuki-Miyaura Cross-Coupling Reactions for Increasing the Efficiency of Tris-Heteroleptic Iridium(III) Emitters. ORGANOMETALLICS. DOI
• (2018). Peak AAA fatty acid homolog contaminants present in the dietary supplement L-Tryptophan associated with the onset of eosinophilia-myalgia syndrome. TOXICOLOGY LETTERS. DOI
• (2018). Structure determination of disease associated peak AAA from L-Tryptophan implicated in the eosinophilia-myalgia syndrome. TOXICOLOGY LETTERS. DOI
• (2018). Tomatidine Is a Lead Antibiotic Molecule That Targets <i>Staphylococcus aureus</i> ATP Synthase Subunit C. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. DOI
• (2017). nterfacial supramolecular biomimetic epoxidation catalyzed by cyclic dipeptides. Supramolecular Chemistry.
• (2017). Targeting IL5Ra with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer. Oncoimmunology.
• Bérubé, C., Barbeau, X., Cardinal, S., Boudreault, P.-L., Bouchard, C., Delcey, N., Lagüe, P., Voyer, N. (2017). Interfacial supramolecular biomimetic epoxidation catalysed by cyclic dipeptides. Supramolecular Chemistry. DOI
• (2017). Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. DOI
• Paquette, M., Vilera-Perez, L.-G., Beaudoin, S., Ekindi-Ndongo, N., Boudreaut, P.-L., Bonin, M.-A., Battista, M.-C., Bentourkia, M., Lopez, A.F., Lecomte, R., Marsault, E., Guérin, B., Sabbagh, R., Leyton, J.V. (2017). Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer. Oncoimmunology. DOI
• (2015). Novel chiral N,N'-dimethyl-1,4-piperazines with metal binding abilities. Tetrahedron.
• (2015). Studies on the regio-and diastereo-selective epoxidation of daphnanes and tiglianes. Tetrahedron Letters.
• Bérubé, C., Cardinal, S., Boudreault, P.-L., Barbeau, X., Delcey, N., Giguère, M., Gleeton, D., Voyer, N. (2015). Novel chiral N,N′-dimethyl-1,4-piperazines with metal binding abilities. Tetrahedron. DOI
• Boudreault, P.-L., Mattler, J.K., Wender, P.A. (2015). Studies on the regio- and diastereo-selective epoxidation of daphnanes and tiglianes. Tetrahedron Letters. DOI
• (2014). Analysis of Subpocket Selectivity and Identification of Potent Selective Inhibitors for Matriptase and Matriptase-2. JOURNAL OF MEDICINAL CHEMISTRY. DOI
• (2014). NEW PEPTIDOMIMETIC INHIBITORS OF MATRIPTASE TO FIGHT INFLUENZA. JOURNAL OF PEPTIDE SCIENCE.
• (2014). Synthesis and characterization of bio-inspired ligands for enantioselective "green" transformations. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY.
• Boudreault, P.-L., Cardinal, S., Voyer, N. (2010). Efficient preparation of 2-aminomethylbiphenyls via suzuki-miyaura reactions. Synlett. DOI
• Boudreault, P.-L., Arseneault, M., Otis, F., Voyer, N. (2008). Nanoscale tools to selectively destroy cancer cells. Chemical Communications. DOI
• Boudreault, P.-L., Voyer, N. (2007). Synthesis, characterization and cytolytic activity of α-helical amphiphilic peptide nanostructures containing crown ethers. Organic and Biomolecular Chemistry. DOI
• (2002). Blue-light-emitting conjugated polymers derived from 2,7-carbazoles. MACROMOLECULAR RAPID COMMUNICATIONS. DOI

Chapitres de livre

• (2021). Inhibitors of Protein–Protein Interactions: Small Molecules, Peptides and Macrocycles. Macrocycles as Inhibitors of Protein–Protein Interactions.

Propriétés intellectuelles

Licences

• TTSP inhibitors for the treatment of SARS-CoV-2. Ebvia. (2021).
• License agreement with Amorchem Therapeutics, Inc. related to patents on steroid alkaloids as inhibitors of bacterial ATP synthase. (2017).
• Research agreement with licence: matriptase inhibitors for the treatment of influenza. (2013).

Brevets

• Antibodies specific for NTSR1 and uses thereof. PCT/CA2019/051216. (2018).
• Antibody conjugate for treating and detecting bladder cancer. PCT/CA2017/051575. (2018).
• Antibody conjugate for treating and detecting bladder cancer. 16/493845. (2018).
• Matriptase inhibitors and therapeutic uses thereof. CA3085853. (2016).

Autres contributions

Cours enseignés à l'UdeS

• CHM720 - Conception et optimisation de médicaments. (2023-2026). (1CR).
• PHR714 - Chimie médicinale avancée. (2023-2025). (2CR).

Divers

• Boudreault, P.-L., Chamberland, S., Larose, A., Millette, G., Langlois, J.-P., Côté-Gravel, J., Brouillette, E., Almeida, D.D., Delbrouck, J.A., Diachenko, I., Jamaa, A.B., Normandin, C., Murza, A., Malouin, F. (2025). In Vitro and in Vivo Activity Profiles of Broad-Spectrum Bacterial Atp Synthase Inhibitors. Ssrn.
• Chamberland, S., Larose, A., Millette, G., Langlois, J.-P., Côté-Gravel, J., Brouillette, E., Almeida, D.D., Delbrouck, J.A., Diachenko, I., Jamaa, A.B., Normandin, C., Murza, A., Malouin, F., Boudreault, P.-L. (2025). In vitro and in vivo activity profiles of broad-spectrum bacterial ATP synthase inhibitors. Biorxiv.
• Gitlin-Domagalska, A., Hassanzadeh, M., Helbik-Maciejewska, A., Lepage, M., Joushomme, A., Désilets, A., Dębowski, D., Boudreault, P.-L., Leduc, R., Rolka, K. (2025). Structural Insights into Frog Skin-Derived Cyclic Peptides as Selective Matriptase Inhibitors. Ssrn.
• Hadjadj, M., Martel, J., Roy, M.-F., Hassanzadeh, M., Giguère, H., Murza, A., Holleran, B.J., Namkung, Y., Froehlich, U., Leduc, R., Auger-Messier, M., Laporte, S.A., Boudreault, P.-L. (2025). Tunable Bias Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Modifications and Allosteric Site Targeting. Biorxiv.
• Brouillette, R.L., Mona, C.E., Desgagné, M., Hassanzedeh, M., Breault, É., Lussier, F., Belleville, K., Longpré, J.-M., Grandbois, M., Boudreault, P.-L., Besserer-Offroy, É., Sarret, P. (2024). A lipidated peptide derived from the C-terminal tail of the vasopressin 2 receptor shows promise as a new b-arrestin inhibitor. Arxiv.
• Joushomme, A., Désilets, A., Champagne, W., Hassanzadeh, M., Lemieux, G., Gravel-Trudeau, A., Lepage, M., Lafrenière, S., Froehlich, U., List, K., Boudreault, P.-L., Leduc, R. (2024). Development of ketobenzothiazole-based peptidomimetic TMPRSS13 inhibitors with low nanomolar potency. Biorxiv.
• Nguyen, D.T., Desgagné, M., Laniel, A., Lavoie, C., Boudreault, P.-L. (2024). Diversity-Oriented Synthesis of Second Generation Guanidinium-Rich Transporters Toward Cell-Selective Penetration. Ssrn.
• Geraldes, P., Robillard, S., Théroux, L., Lemay, A., Ouellet, M., Lizotte, F., Boudreault, P.-L. (2024). The apelinergic system accelerates skin repair of full-thickness excisional wounds in a diabetic murine model. Research Square.
• Robillard, S., Trân, K., Brazeau, T., Boisvert, E., Lizotte, F., Auger-Messier, M., Boudreault, P.-L., Marsault, É., Geraldes, P. (2023). Apelin improves angiogenesis and blood flow reperfusion following lower limb ischemia in diabetic mice. Biorxiv.
• Delbrouck, J.A., Murza, A., Diachenko, I., Jamaa, A.B., Devi, R., Larose, A., Chamberland, S., Malouin, F., Boudreault, P.-L. (2023). From Garden to Lab: C-3 Chemical Modifications of Tomatidine Unveil Broad-Spectrum Atp Synthase Inhibitors to Combat Bacterial Resistance. Ssrn.
• Leblanc, E., Le Moal, E., Liu, Y., Théroux, L., Bonin, M.-A., Schüler, S.C., Boudreault, P.-L., Bentzinger, C.F. (2023). Identification of ECM-Derived Skeletal Muscle Stem Cell Adhesion Motifs Using SPOT-Synthesis-Based Peptide Arrays. Ssrn.
• Shapira, T., Monreal, I.A., Dion, S.P., Jager, M., Désilets, A., Olmstead, A.D., Vandal, T., Buchholz, D.W., Imbiakha, B., Gao, G., Chin, A., Rees, W.D., Steiner, T., Nabi, I.R., Marsault, E., Sahler, J., August, A., van de Walle, G., Whittaker, G.R., ... Jean, F. (2021). A novel highly potent inhibitor of TMPRSS2-like proteases blocks SARS-CoV-2 variants of concern and is broadly protective against infection and mortality in mice. bioRxiv.